A new Genomic Test – TML (tumour mutational load is emerging as an important indicator of sensitivity to immune checkpoint inhibitors and may indicate your likely response to immunotherapy.
The use of immune checkpoint inhibitors (immunotherapies) in tumours with a higher TML has been shown to be associated with improved overall survival rates.
How could this benefit me?
The Tumour Mutational Load assay has been designed in response to the need to determine if treatment utilising immune checkpoint inhibitors is likely to be of benefit in your particular clinical circumstances.
For some cancer types, immunotherapy drugs are not listed on the Australian Pharmaceutical Benefits Scheme, and they would incur a large out-of-pocket expense.
We consider this test an important step in gaining as much information as possible prior to deciding on whether to progress with these particular group of drugs.
What is Tumour Mutational Load?
Cancer is a complex disease, caused by a wide range of
genetic mutations that can be present in many combinations.
Tumour mutational load (TML), or tumour mutational burden (TMB), is a measure of the number of mutations within a tumour genome. TML can vary greatly between tumour types, ranging from just a few mutations to thousands of mutations within a tumour.